Trial Profile
A Double-blind, Randomized, Three-period, Three-way Crossover Design, Placebo Controlled Single Dose Study to Assess the Bioavailability of Sodium Oligo-mannurarate (GV-971) Capsule 150 mg, 300mg, 450mg in Healthy Chinese Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Feb 2018
Price :
$35
*
At a glance
- Drugs Sodium oligomannurarate (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors Shanghai Green Valley Pharmaceutical
- 06 Feb 2018 Status changed from recruiting to completed.
- 12 Dec 2016 New trial record